Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks”In the company’s words, NCT04183166 on ClinicalTrials.gov
- Tested for
- Squamous Cell Carcinoma of Head and Neck
- Main trialPhase 1/2
- “This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).”In the company’s words, NCT04183166 on ClinicalTrials.gov
Other drugs for Squamous Cell Carcinoma of Head and Neck
- APG-157Aveta Biomics, Inc. · Phase 3
- PembrolizumabMerck & Co. · Phase 2/3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- FiclatuzumabAVEO Pharmaceuticals, Inc. · Phase 3
- SYS6002CSPC · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
Coming up1
- 30 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 30 Dec 2027 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | |
| Phase 1Completed | 8 Oct 2024 | A Trial Evaluating TG4050 in Ovarian Carcinoma. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026